Marshutina N V
Farmakol Toksikol. 1978 Sep-Oct;41(5):568-75.
In rabbits with experimental myocardial infarction (EMI) complicated by arrhthmias the antiarrhythmic action of neocompensan (haemodesum) was ascertained for the first time. In the acute period of EMI no electrolytes shifts in the blood serum of the animals were disclosed and this justified the antiarrhythmis effect of neocompensan, occurring during the first 24 hours of the experiment, to be attributed to the influence of polyvinylpyrrolidine. Besides, the drug produced in rabbits with EMI deceleration of the total blood coagulation. Following administration of neocompensan (haemodesum) no arrhythmias were recorded. Thus, neocompensan (haemodesum) displays antiarrhytmic action, has a beneficial effect on the blood coagulation system and as a result reduces the lethality among rabbits with EMI, complicated by arrhythmias.
在患有实验性心肌梗死(EMI)并伴有心律失常的兔子身上,首次确定了新复方制剂(血代)的抗心律失常作用。在EMI急性期,未发现动物血清中的电解质有变化,这证明了新复方制剂在实验的最初24小时内产生的抗心律失常作用归因于聚乙烯吡咯烷酮的影响。此外,该药物使患有EMI的兔子的全血凝固减慢。给予新复方制剂(血代)后未记录到心律失常。因此,新复方制剂(血代)具有抗心律失常作用,对凝血系统有有益影响,从而降低了患有EMI并伴有心律失常的兔子的死亡率。